（一）审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 监事会认为： 证券代码：603883 证券简称：老百姓 公告编号：2025-039 老百姓大药房连锁股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性和完整性承担法律责任。 一、监事会会议召开情况 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2025 年 8 月 15 日 发出召开第五届监事会第七次会议的通知，会议于 2025 年 8 月 25 日以现场表 决的方式召开。会议应参与表决的监事 3 名，实际参与表决的监事 3 名。本次 会议经过了适当的通知程序，会议程序符合《公司法》等有关法律法规及《公 司章程》的规定，会议及通过的决议合法有效。 二、监事会会议审议情况 会议审议并通过了如下议案： （1）公司2025年半年度报告编制和审议符合法律、法规、《公司章程》和 公司内部管理制度的规定。 （2）半年度报告的内容和格式符合中国证监会和上海证券交易所的有关规 定和要求，所包含的半年度报告能全面、真实地反映公司2025年半年度经营和 财务管理状况。 （3）未发现参 ...

证券日报网讯 8月25日晚间，老百姓发布公告称，2025年半年度公司实现营业收入10，774，312，515 元，同比下降1.51%；归属于上市公司股东的净利润为397，863，893元，同比下降20.86%。 （文章来源：证券日报） ...

Core Viewpoint - The company reported a decline in both revenue and net profit for the first half of the year, attributing the decrease to changes in business operations and increased costs [1] Financial Performance - The company achieved operating revenue of 10.774 billion yuan, a year-on-year decrease of 1.51% [1] - The net profit attributable to shareholders was 398 million yuan, reflecting a year-on-year decline of 20.86% [1] Business Operations - The decline in net profit is primarily due to an increase in the sales proportion of new retail business, which led to a decrease in gross margin compared to the previous year [1] - There was also an increase in research and development expenses compared to the same period last year, contributing to the overall decline in profitability [1]

（文章来源：证券日报） 证券日报网讯 8月25日晚间，老百姓发布公告称，公司第五届监事会第七次会议审议通过了《关于公司 及其摘要的议案》等多项议案。 ...

证券日报网讯 8月25日晚间，老百姓发布公告称，公司第五届董事会第十次会议审议通过了《关于公司 及其摘要的议案》等多项议案。 （文章来源：证券日报） ...

Group 1: Company Performance - The company reported a revenue of 10.77 billion and a net profit of 398 million for the first half of 2025, with a total of 15,385 stores across 18 provinces and over 150 cities [1] - In the second quarter, the company's main business in pharmaceutical retail achieved a positive growth of 0.2%, showing significant improvement compared to the first quarter [1] - The operating cash flow improved significantly, with a year-on-year increase of 165.92% during the reporting period [1] Group 2: Industry Trends - The number of pharmacies in China is expected to see a negative growth turning point in 2024, with a net decrease of 3,166 stores in the first quarter of 2025, bringing the total below 700,000 [2] - The top 100 chain pharmacies' sales scale is projected to account for 60.9% of the national retail market share in 2024, indicating a 2.1 percentage point increase from 2023 [2] - The industry is experiencing accelerated consolidation, with a focus on large chains, enhancing the head effect [2] Group 3: Health Management Initiatives - The company positions retail pharmacies as a core scene for health promotion, focusing on comprehensive health management covering disease prevention, monitoring, medication follow-up, and health guidance [3] - As of June 30, the company had 1,729 stores qualified for outpatient chronic disease management and had served over 20.51 million chronic disease patients [3] - The company conducted over 37,000 health education sessions for customers, both online and offline [3] Group 4: Digital Transformation and AI Integration - The company is advancing from "digital intelligence" to "intelligence" by launching an enterprise-level AI knowledge Q&A system in collaboration with Tencent Health [4] - The AI system covers three core business areas: medical insurance policies, store operations, and human resources, enabling precise responses to complex business needs [4] - The company aims to deepen AI applications in various fields, including operations, procurement, sales, and new retail [4]

Core Viewpoint - The company reported a stable performance in the first half of 2025, with a focus on enhancing core competitiveness through customer-centric reforms and digital transformation [1][4]. Financial Performance - The company achieved operating revenue of 10.77 billion yuan and a net profit attributable to shareholders of 398 million yuan in the first half of 2025 [1]. - The cash flow from operating activities significantly improved, increasing by 165.92% year-on-year [1]. Market Position and Strategy - The company operates a network of 15,385 stores across 18 provinces and over 150 cities, with 9,784 direct-operated stores and 5,601 franchised stores [1]. - The company is optimizing its store network by focusing on franchise and alliance models to capture the existing market, enhancing market share in advantageous areas [2]. Industry Trends - The retail pharmacy industry is experiencing a decline in the total number of stores, with a net decrease of 3,166 stores in the first quarter of 2025, bringing the total below 700,000 [2]. - The top 100 chain pharmacies are increasing their market share, accounting for 60.9% of the national retail market in 2024, up 2.1 percentage points from 2023 [2]. Service and Community Engagement - The company has established 1,729 stores with outpatient chronic disease qualifications and has served over 20.51 million chronic disease patients [3]. - The company launched the "Altruism and Morale Enhancement" project to promote a culture of altruism among employees and customers, transitioning stores from transactional to relationship-based services [3]. Digital Transformation and AI Integration - The company is deepening its digital transformation, optimizing logistics, inventory management, and new retail strategies to meet diverse consumer health needs [4]. - The inventory turnover days decreased to 89 days, and online sales reached approximately 1.49 billion yuan, growing by 32% year-on-year [4]. - The company has partnered with Tencent Health to launch an AI-driven knowledge Q&A system, enhancing operational efficiency across key business areas [4].

Core Insights - The company reported a revenue of 10.77 billion and a net profit of 398 million for the first half of 2025, with a total of 15,385 stores across 18 provinces and over 150 cities [1] - The company is focusing on customer-centric reforms and enhancing core competitiveness through organizational efficiency, AI empowerment, and professional services [1] - The retail pharmacy sector is undergoing significant transformation, with a trend towards consolidation among large chains, as smaller players are being phased out [2] Financial Performance - The company's retail pharmacy revenue showed positive growth in Q2, with all segments experiencing an increase in gross margin, although the overall retail gross margin slightly decreased due to changes in the sales mix [1] - Operating cash flow improved significantly, with a year-on-year increase of 165.92% [1] Market Strategy - The company is optimizing its store network by focusing on franchise and alliance models to capture market share, with 71% of new store openings being franchises, an increase of 41.8 percentage points year-on-year [2] - The total number of alliance stores exceeded 22,000, with alliance business achieving a delivery sales volume of 229 million, up 28.4% year-on-year [2] Digital Transformation - The company is advancing its digital transformation, optimizing logistics and inventory management, and enhancing new retail strategies, resulting in a reduction of inventory turnover days to 89, down 13 days year-on-year [3] - Online sales reached approximately 1.49 billion, reflecting a year-on-year growth of 32% [3] Future Outlook - The company aims to transition from being a "pharmaceutical transporter" to a "health CEO," providing comprehensive health solutions and emotional value to customers [3] - The company plans to deepen AI applications across various business areas to enhance operational efficiency and respond to diverse consumer health needs [3]

证券代码：603883 证券简称：老百姓 公告编号：2025-044 老百姓大药房连锁股份有限公司 关于回购注销剩余限制性股票的公告 5、2022 年 8 月 30 日，公司召开了第四届董事会第二十二次会议和第四届 监事会第十九次会议，审议通过《关于调整 2022 年限制性股票激励计划首次授 予激励对象名单及授予权益数量的议案》《关于向 2022 年限制性股票激励计划 激励对象首次授予限制性股票的议案》。公司独立董事对相关事项发表了独立意 见，公司监事会对首次授予相关事项进行了核实。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日召开了第五届董事会第十次会议和第五届监事会第七次会议审议通过了《关于 回购注销剩余限制性股票的议案》。鉴于 2022 年限制性股票激励计划激励对象 中 32 人已离职及首次授予第三个解除限售期、预留授予第二个解除限售期公司 层面业绩不达标，公司决定回购注销 2022 年限制性股票激励计划剩余的限制性 股票合计 1,20 ...

老百姓大药房连锁股份有限公司 关于回购注销限制性股票通知债权人的公告 证券代码：603883 证券简称：老百姓 公告编号：2025-045 由于公司本次回购注销剩余限制性股票涉及注册资本变更，依据《中华人民 共和国公司法》等相关法律、法规的规定，公司特此通知债权人，债权人自接到 公司通知起 30 日内、未接到通知者自本公告披露之日起 45 日内，有权凭有效债 权文件及相关凭证要求公司清偿债务或者提供相应担保。债权人如逾期未向公司 申报债权，不会因此影响其债权的有效性，相关债务（义务）将由公司根据原债 权文件的约定继续履行。债权人未在规定期限内行使上述权利的，本次回购注销 将按法定程序继续实施。 公司各债权人如要求公司清偿债务或提供相应的担保，应根据《中华人民共 和国公司法》等法律、法规的有关规定向公司提出书面要求，并随附有关证明文 件。债权申报具体如下： 1、申报时间：2025 年 8 月 26 日至 2025 年 10 月 10 日 特此公告。 老百姓大药房连锁股份有限公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任 ...